{"title":"Update in pathological classification of cervical intraepithelial neoplasia and cervical cancer","authors":"Meenakshi Swain","doi":"10.4103/jclgtp.jclgtp_17_23","DOIUrl":null,"url":null,"abstract":"Cervical cancer is the second most common cancer in Indian women and the second leading cause of death, accounting for up to 29% of all malignancies. Human papillomavirus (HPV) is now established as the causative agent of most cervical squamous cell carcinomas (SCCs) and a large majority of adenocarcinomas, except a few HPV-independent subtypes. Both squamous and glandular lesions have precursor lesions called squamous intraepithelial lesions (SILs) and adenocarcinoma in situ (AIS), respectively. The term SIL replaces the earlier cervical intraepithelial neoplasia (CIN), in both cytology and histology specimens. The three-tier classification of CIN1, CIN2 and CIN3 is now a two-tier system, namely low grade SIL (LSIL) and high grade SIL (HSIL). HSIL may further be classified as HSIL CIN2 / HSIL CIN3 as applicable, since HSIL CIN2 has a higher rate of regression, especially in younger women. HPV-independent SIL and SCC are almost nonexistent. In contrast, AIS and adenocarcinoma have established HPV-independent types, many with an aggressive behavior and a worse prognosis. HPV-independent adenocarcinomas have gastric, clear cell, mesonephric and endometrioid types. Certain morphologic features and demonstration of HPV by immunohistochemistry (IHC) for p16, a good surrogate marker for HPV, are among the essential and desirable criteria outlined by the fifth edition of the World Health Organization published in 2020, for diagnosis of the HPV-associated cervical carcinomas. High-risk HPV testing can also be done by molecular techniques such as DNA and mRNA in situ hybridization. These methods are not widely available and are expensive; hence, IHC is a good alternative.","PeriodicalId":476164,"journal":{"name":"Journal of Colposcopy and Lower Genital Tract Pathology","volume":"17 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Colposcopy and Lower Genital Tract Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jclgtp.jclgtp_17_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Cervical cancer is the second most common cancer in Indian women and the second leading cause of death, accounting for up to 29% of all malignancies. Human papillomavirus (HPV) is now established as the causative agent of most cervical squamous cell carcinomas (SCCs) and a large majority of adenocarcinomas, except a few HPV-independent subtypes. Both squamous and glandular lesions have precursor lesions called squamous intraepithelial lesions (SILs) and adenocarcinoma in situ (AIS), respectively. The term SIL replaces the earlier cervical intraepithelial neoplasia (CIN), in both cytology and histology specimens. The three-tier classification of CIN1, CIN2 and CIN3 is now a two-tier system, namely low grade SIL (LSIL) and high grade SIL (HSIL). HSIL may further be classified as HSIL CIN2 / HSIL CIN3 as applicable, since HSIL CIN2 has a higher rate of regression, especially in younger women. HPV-independent SIL and SCC are almost nonexistent. In contrast, AIS and adenocarcinoma have established HPV-independent types, many with an aggressive behavior and a worse prognosis. HPV-independent adenocarcinomas have gastric, clear cell, mesonephric and endometrioid types. Certain morphologic features and demonstration of HPV by immunohistochemistry (IHC) for p16, a good surrogate marker for HPV, are among the essential and desirable criteria outlined by the fifth edition of the World Health Organization published in 2020, for diagnosis of the HPV-associated cervical carcinomas. High-risk HPV testing can also be done by molecular techniques such as DNA and mRNA in situ hybridization. These methods are not widely available and are expensive; hence, IHC is a good alternative.